Search

Your search keyword '"Usmani, Saad Z"' showing total 18 results
Start Over Author "Usmani, Saad Z" Journal blood advances
18 results on '"Usmani, Saad Z"'

1. Patterns of CRS with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy

Author

Hamadeh, Issam S., Shekarkhand, Tala, Rueda, Colin, Firestone, Ross S., Wang, Alice X., Korde, Neha, Hultcrantz, Malin L., Lesokhin, Alexander M., Mailankody, Sham, Hassoun, Hani, Shah, Urvi A., Maclachlan, Kylee, Rajeeve, Sridevi, Patel, Dhwani, Shah, Gunjan L., Scordo, Michael, Lahoud, Oscar B., Chung, David J., Landau, Heather J., Giralt, Sergio, Usmani, Saad Z., and Tan, Carlyn R.

Published
2024
Full Text
View/download PDF

2. Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies

Author

Howard, Anna J., Concepcion, Isabel, Wang, Alice X., Hamadeh, Issam S., Hultcrantz, Malin, Mailankody, Sham, Tan, Carlyn, Korde, Neha, Lesokhin, Alexander M., Hassoun, Hani, Shah, Urvi A., Maclachlan, Kylee H., Rajeeve, Sridevi, Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar B., Chung, David J., Giralt, Sergio, Usmani, Saad Z., and Firestone, Ross S.

Published
2024
Full Text
View/download PDF

3. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma

Author

Firestone, Ross S., McAvoy, Devin, Shekarkhand, Tala, Serrano, Edith, Hamadeh, Issam, Wang, Alice, Zhu, Menglei, Qin, Wei Ge, Patel, Dhwani, Tan, Carlyn R., Hultcrantz, Malin, Mailankody, Sham, Hassoun, Hani, Shah, Urvi S., Korde, Neha, Maclachlan, Kylee H., Landau, Heather J., Scordo, Michael, Shah, Gunjan L., Lahoud, Oscar B., Giralt, Sergio, Murata, Kazunori, Hosszu, Kinga K., Chung, David J., Lesokhin, Alexander M., and Usmani, Saad Z.

Published
2024
Full Text
View/download PDF

5. Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX

Author

Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, and Dimopoulos, Meletios A.

Published
2024
Full Text
View/download PDF

6. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Author

Shah, Urvi A., Moshier, Erin, Derkach, Andriy, Huang, Yuanhui, Mailankody, Sham, Tan, Carlyn R., Maclachlan, Kylee, Hultcrantz, Malin, Korde, Neha, Hassoun, Hani, Thibaud, Santiago, Sanchez, Larysa, Rodriguez, Cesar, Richard, Shambavi, Richter, Joshua, Rossi, Adriana, Cho, Hearn Jay, Lesokhin, Alexander, Chari, Ajai, Usmani, Saad Z., Jagannath, Sundar, Parekh, Samir, and Gallagher, Emily J.

Published
2024
Full Text
View/download PDF

9. Impact of second primary malignancy postautologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis

Author

Ragon, Brittany Knick, Shah, Mithun Vinod, D’Souza, Anita, Estrada-Merly, Noel, Gowda, Lohith, George, Gemlyn, de Lima, Marcos, Hashmi, Shahrukh, Kharfan-Dabaja, Mohamed A., Majhail, Navneet S., Banerjee, Rahul, Saad, Ayman, Hildebrandt, Gerhard C., Mian, Hira, Abid, Muhammad Bilal, Battiwalla, Minoo, Lekakis, Lazaros J., Patel, Sagar S., Murthy, Hemant S., Nieto, Yago, Strouse, Christopher, Badawy, Sherif M., Al Hadidi, Samer, Dholaria, Bhagirathbhai, Aljurf, Mahmoud, Vesole, David H., Lee, Cindy H., Pawarode, Attaphol, Gergis, Usama, Miller, Kevin C., Holmberg, Leona A., Afrough, Aimaz, Solh, Melhem, Munshi, Pashna N., Nishihori, Taiga, Anderson, Larry D., Jr., Wirk, Baldeep, Kaur, Gurbakhash, Qazilbash, Muzaffar H., Shah, Nina, Kumar, Shaji K., and Usmani, Saad Z.

Published
2023
Full Text
View/download PDF

10. Unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies

Author

Howard, Anna J, primary, Concepcion, Isabel, additional, Wang, Alice X., additional, Hamadeh, Issam S., additional, Hultcrantz, Malin L., additional, Mailankody, Sham, additional, Tan, Carlyn Rose, additional, Korde, Neha, additional, Lesokhin, Alexander M., additional, Hassoun, Hani, additional, Shah, Urvi A., additional, Maclachlan, Kylee H., additional, Rajeeve, Sridevi, additional, Landau, Heather J., additional, Scordo, Michael, additional, Shah, Gunjan L, additional, Lahoud, Oscar B, additional, Chung, David J., additional, Giralt, Sergio A, additional, Usmani, Saad Z, additional, and Firestone, Ross S., additional

Published
2024
Full Text
View/download PDF

11. Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy

Author

Hamadeh, Issam S., primary, Shekarkhand, Tala, additional, Rueda, Colin Joseph, additional, Firestone, Ross S., additional, Wang, Alice X., additional, Korde, Neha, additional, Hultcrantz, Malin L., additional, Lesokhin, Alexander M., additional, Mailankody, Sham, additional, Hassoun, Hani, additional, Shah, Urvi A., additional, Maclachlan, Kylee H., additional, Rajeeve, Sridevi, additional, Patel, Dhwani, additional, Shah, Gunjan L, additional, Scordo, Michael, additional, Lahoud, Oscar B, additional, Chung, David J., additional, Landau, Heather J., additional, Giralt, Sergio A, additional, Usmani, Saad Z, additional, and Tan, Carlyn Rose, additional

Published
2024
Full Text
View/download PDF

13. CD8 effector T cells enhance response in BCMA-exposed and -naïve multiple myeloma.

Author

Firestone, Ross S, primary, McAvoy, Devin, additional, Shekarkhand, Tala, additional, Serrano, Edith, additional, Hamadeh, Issam, additional, Wang, Alice, additional, Zhu, Menglei, additional, Patel, Dhwani, additional, Tan, Carlyn Rose, additional, Hultcrantz, Malin, additional, Mailankody, Sham, additional, Hassoun, Hani, additional, Shah, Urvi A, additional, Korde, Neha, additional, Maclachlan, Kylee H., additional, Landau, Heather J., additional, Scordo, Michael, additional, Shah, Gunjan L, additional, Lahoud, Oscar B, additional, Giralt, Sergio A., additional, Murata, Kazunori, additional, Hosszu, Kinga K., additional, Chung, David J., additional, Lesokhin, Alexander M, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

14. Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Author

Shah, Urvi A, primary, Moshier, Erin Laverne, additional, Derkach, Andriy, additional, Huang, Yuanhui, additional, Mailankody, Sham, additional, Tan, Carlyn Rose, additional, Maclachlan, Kylee H., additional, Hultcrantz, Malin, additional, Korde, Neha, additional, Hassoun, Hani, additional, Thibaud, Santiago, additional, Sanchez, Larysa, additional, Rodriguez, Cesar, additional, Richard, Shambavi, additional, Richter, Joshua, additional, Rossi, Adriana, additional, Cho, Hearn J, additional, Lesokhin, Alexander M, additional, Chari, Ajai, additional, Usmani, Saad Z., additional, Jagannath, Sundar, additional, Parekh, Samir, additional, and Gallagher, Emily Jane, additional

Published
2023
Full Text
View/download PDF

15. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis

Author

Ragon, Brittany Knick, primary, Shah, Mithun Vinod, additional, D'Souza, Anita, additional, Estrada-Merly, Noel, additional, Gowda, Lohith, additional, George, Gemlyn, additional, DeLima, marcos, additional, Hashmi, Shahrukh, additional, Kharfan-Dabaja, Mohamed A, additional, Majhail, Navneet S, additional, Banerjee, Rahul, additional, Saad, Ayman, additional, Hildebrandt, Gerhard C., additional, Mian, Hira, additional, Abid, Muhammad Bilal, additional, Battiwalla, Minoo, additional, Lekakis, Lazaros J., additional, Patel, Sagar S., additional, Murthy, Hemant S., additional, Nieto, Yago, additional, Strouse, Christopher S, additional, Badawy, Sherif M., additional, Al Hadidi, Samer AI, additional, Dholaria, Bhagirathbhai, additional, Aljurf, Mahmoud, additional, Vesole, David H, additional, Lee, Cindy H, additional, Pawarode, Attaphol, additional, Gergis, Usama, additional, Miller, Kevin Charles, additional, Holmberg, Leona A, additional, Afrough, Aimaz, additional, Solh, Melhem M, additional, Munshi, Pashna, additional, Nishihori, Taiga, additional, Anderson, Larry D., additional, Wirk, Baldeep, additional, Kaur, Gurbakhash, additional, Qazilbash, Muzaffar H, additional, Shah, Nina, additional, Kumar, Shaji K, additional, and Usmani, Saad Z., additional

Published
2023
Full Text
View/download PDF

16. Daratumumab in Myeloma Patients With Early or Late Relapse After Initial Therapy: Subgroup Analysis of CASTOR and POLLUX

Author

Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z., Yoon, Sung-Soo, Usmani, Saad Z., Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J. Blake, Carson, Robin, and Dimopoulos, Meletios A.

Abstract

•Post hoc analyses of CASTOR/POLLUX showed PFS and depth of response benefit with daratumumab, regardless of relapse timing (early or late)•These results support daratumumab use in patients with MM who relapse early after initial therapy and have functional high-risk disease

Published
2023
Full Text
View/download PDF

17. Artificial Intelligence Enabled Interpretation of ECG Images to Predict Hematopoietic Cell Transplantation Toxicity.

Author

Shaffer BC, Brown S, Chinapen S, Mangold K, Lahoud OB, Lopez-Jimenez F, Schaffer WL, Liu JE, Giralt SA, Devlin SM, Shah GL, Scordo M, Papadopoulos EB, Landau HJ, Usmani SZ, Perales MA, Friedman P, Gersh B, Attia I, Noseworthy P, and Kosmidou I

Abstract

Artificial intelligence enabled interpretation of electrocardiogram waveform images (AI-ECG) can identify patterns predictive of future adverse cardiac events. We hypothesized such an approach, which is well described in general medical and surgical patients, would provide prognostic information with respect to the risk of cardiac complications and overall mortality in patients undergoing hematopoietic cell transplantation (HCT) for blood malignancy. We retrospectively subjected ECGs obtained pre-HCT to an externally trained, deep learning model designed to predict risk of atrial fibrillation (AF). Included were 1,377 patients (849 autologous HCT and 528 allogeneic HCT recipients). Median follow-up was 2.9 years. The three-year cumulative incidence of AF was 9% (95% CI: 7-12%) in autologous HCT patients and 13% (10-16%) in allogeneic HCT patients. In the entire cohort, pre-HCT AI-ECG estimate of AF risk correlated highly with development of clinical AF (Hazard Ratio (HR) 7.37, 3.53-15.4, p <0.001), inferior overall survival (HR: 2.4; 1.3-4.5, p = 0.004), and greater risk of non-relapse mortality (HR 3.36, 1.39-8.13, p = 0.007), without increased risk of relapse. Significant associations with mortality were only noted in allo HCT recipients, where the risk of non-relapse mortality was greater. Compared to calcineurin inhibitor-based graft versus host disease prophylaxis, the use of post-transplantation cyclophosphamide resulted in greater 90-day incidence of AF (13% versus 5%, p = 0.01), corresponding to temporal changes in AI-ECG AF prediction post HCT. In summary, AI-ECG can inform risk of post-transplant cardiac outcomes and survival in HCT patients and represents a novel strategy for personalized risk assessment after HCT., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

18. Alliance A061202: Ixazomib, pomalidomide and dexamethasone for lenalidomide-refractory multiple myeloma in first relapse.

Author

Voorhees PM, Suman V, Efebera YA, Raje N, Tuchman SA, Rodriguez C, Laubach JP, Bova-Solem M, Carlisle D, Usmani SZ, McCarthy PL, and Richardson PG

Abstract

Optimal therapy for the growing number of patients with lenalidomide (LEN)-refractory multiple myeloma (MM) in first relapse remains poorly defined. We therefore undertook a randomized phase II study evaluating the efficacy and safety of combining the oral proteasome inhibitor ixazomib (IXA) with pomalidomide (POM) and dexamethasone (DEX) for this patient population. The overall response rate (ORR) for POM-DEX was 43.6% and 63.2% for IXA-POM-DEX. Depth of response, as measured by attainment of a very good partial response or better favored the triplet over the doublet, 28.9% vs 5.1%, respectively (p = 0.0063). A pre-planned interim analysis after 75% of the progression events had occurred demonstrated a progression-free survival (PFS) advantage favoring IXA-POM-DEX that crossed the predefined boundary of superiority, leading to release of the study results. With additional follow-up, the median PFS for POM-DEX was 7.5 months (95% confidence interval [CI] 4.8 - 13.6 months) vs 20.3 months for IXA-POM-DEX (95% CI 7.7 - 26.0 months, hazard ratio 0.437 [upper 90% bound = 0.657]). ORR and median PFS for the 26 of 30 eligible patients who crossed over from the doublet to the triplet at progression was 23.1% and 5.6 months, respectively. Overall survival was similar between the two groups. More hematologic toxicities were seen with the triplet, but non-hematologic adverse events were similar between the two arms. Our data support further testing of this all-oral triplet vs current standard triplet therapy in the context of phase III studies for patients with LEN-refractory disease in first relapse. This trial is registered at www.clinicaltrials.gov as NCT02004275., (Copyright © 2024 American Society of Hematology.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results